Timothy J. Guzi
Casma Therapeutics (United States)(US)
Publications by Year
Research Areas
Ubiquitin and proteasome pathways, Computational Drug Discovery Methods, Protein Structure and Dynamics, Cancer-related Molecular Pathways, DNA Repair Mechanisms
Most-Cited Works
- → Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor(2010)557 cited
- → Precision Targeted Therapy with BLU-667 for RET-Driven Cancers(2018)388 cited
- → First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway(2015)313 cited
- → A precision therapy against cancers driven by KIT/PDGFRA mutations(2017)210 cited
- → Discovery of Dinaciclib (SCH 727965): A Potent and Selective Inhibitor of Cyclin-Dependent Kinases(2010)175 cited
- → Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening(2011)171 cited
- → Discovery of BLU-945, a Reversible, Potent, and Wild-Type-Sparing Next-Generation EGFR Mutant Inhibitor for Treatment-Resistant Non-Small-Cell Lung Cancer(2022)154 cited
- → Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma(2019)108 cited
- → Discovery of pyrazolo[1,5-a]pyrimidine-based CHK1 inhibitors: A template-based approach—Part 2(2010)74 cited
- → Discovery of pyrazolo[1,5-a]pyrimidine-based CHK1 inhibitors: A template-based approach—Part 1(2010)68 cited